RxDoctor Payments Data

James Dean, MD

Neurology · Tulsa, OKNPI 1346270493

Payments from drug & device makers

$3,898in general payments, 2019–2025

Across 194 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$626
  • Lilly USA, LLC$508
  • Novartis$306
  • AbbVie$288
  • Biogen$236
  • Amgen$199
  • plus $2K from 36 others

What the payments were for

  • Speaking & faculty fees$602%
  • Food & beverage$3,75796%
  • Education$812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,898 in reported general payments places this provider in the 55th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$116,909
Medicare patients
744
Services billed
1,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$579,327
Gamunex-CImmune Globul G/Gly/Iga Avg 4651$227,584
AptiomEslicarbazepine Acetate52$114,412
CopaxoneGlatiramer Acetate13$74,300
Rivastigmine184$35,504
Aimovig AutoinjectorErenumab-Aooe42$31,485
Memantine Hcl834$21,274
NeuproRotigotine13$20,757
Lamictal XrLamotrigine12$20,338
UbrelvyUbrogepant14$16,910
NeurontinGabapentin11$13,356
Pyridostigmine Bromide ErPyridostigmine Bromide19$11,317
Donepezil Hcl479$9,176
Carbamazepine ErCarbamazepine48$7,619
Lamotrigine ErLamotrigine33$6,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$19$227,58451 claims
Sunovion Pharmaceuticals Inc.Aptiom$104$114,41252 claims
Teva Pharmaceuticals USA, Inc.Copaxone$60$74,30013 claims
AbbVieUbrelvy$288$16,91014 claims
Upsher-smith Laboratories LLCTopiramate$13$1,35369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →